Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00078832
Registration number
NCT00078832
Ethics application status
Date submitted
8/03/2004
Date registered
9/03/2004
Date last updated
6/10/2021
Titles & IDs
Public title
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
Query!
Scientific title
International Breast Cancer Intervention Study
Query!
Secondary ID [1]
0
0
EU-20227
Query!
Secondary ID [2]
0
0
ISRCTN31488319
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IBIS II
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - anastrozole
Treatment: Drugs - placebo
Experimental: anastrozole - anastrozole 1mg
Placebo Comparator: placebo - anastrozole 1mg PLACEBO
Treatment: Drugs: anastrozole
aromatase inhibitor
Treatment: Drugs: placebo
Arimidex placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Development of histologically confirmed breast cancer, both invasive and non-invasive with median follow-up at 5 years
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Dec 2013
Query!
Secondary outcome [1]
0
0
Breast cancer mortality with median follow-up at 10 years
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Dec 2018
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
- Meets at least 1 of the relative risk factors based on age as follows:
- 45 to 70 years of age:
- First-degree relative who developed breast cancer at = 50 years of age
- First-degree relative who developed bilateral breast cancer
- Two or more first- or second-degree relatives who developed breast cancer or
ovarian cancer
- Participants having both relatives who are second degree and on the
opposite sides of the family must have at least one that was diagnosed
at = 50 years of age
- Nulliparous (or first birth at = 30 years of age) and a first-degree
relative who developed breast cancer
- Benign biopsy with proliferative disease and a first-degree relative who
developed breast cancer
- Mammographic opacity covering at least 50% of the breast in the absence of
hormone replacement therapy within the past 3 months
- 60 to 70 years of age:
- First-degree relative with breast cancer at any age
- Age at menopause = 55 years
- Nulliparous or age at first birth = 30 years
- 40 to 44 years of age:
- Two or more first- or second-degree relatives who developed breast cancer or
ovarian cancer at = 50 years of age
- First-degree relative with bilateral breast cancer who developed the first
breast cancer at = 50 years of age
- Nulliparous (or first birth at = 30 years of age) and a first-degree
relative who developed breast cancer at = 40 years of age
- Benign biopsy with proliferative disease and a first-degree relative who
developed breast cancer at = 40 years of age
- All age groups (40 to 70 ears of age) with a 10-year risk > 5% who do not fit into the
above categories are allowed
- Clearly apparent family history AND/OR other risk factors indicating appropriate
increased risk of breast cancer for age
- The following prior breast conditions are allowed (for all age groups):
- Lobular carcinoma in situ
- Atypical ductal or lobular hyperplasia in a benign lesion
- Ductal carcinoma in-situ (DCIS), diagnosed within the past 6 months, and treated
by mastectomy
- No evidence of breast cancer on mammogram within the past year
- Hormone receptor status:
- For patients with prior DCIS, estrogen- or progesterone-receptor status must have
been positive
- Must have had greater than or equal to 5% positive cells
PATIENT CHARACTERISTICS:
Age
- 40 to 70
Sex
- Female
Menopausal status
- Postmenopausal, defined as at least 1 of the following:
- Over 60 years of age
- Bilateral oophorectomy
- = 60 years of age with a uterus and amenorrhea for at least 12 months
- = 60 years of age without a uterus and with follicle-stimulating hormone levels >
30 IU/L
Performance status
- Not specified
Life expectancy
- At least 10 years
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Psychologically and physically suitable to receive 5 years of anti-estrogen therapy
- No cancer within the past 5 years except non-melanoma skin cancer or carcinoma in situ
of the cervix
- No evidence of osteoporosis or fragility fractures within the spine
- Participants with a T-score > minus 4 and no more than 2 fragility fractures are
allowed
- No concurrent severe disease that would place the participant at unusual risk or
confound the results of the study
- No other medical condition that would preclude the ability to receive the study
treatment
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- No prior tamoxifen, raloxifene, or other selective estrogen receptor modulator (SERM)
use for more than 6 months in duration unless an IBIS-I participant (must have been
off trial therapy for at least 5 years.
- No concurrent tamoxifen, raloxifene, or other SERM
- No concurrent estrogen-based hormone replacement therapy
- No concurrent systemic estrogen replacement therapy, including vaginal estrogen
preparations
Radiotherapy
- Not specified
Surgery
- See Disease Characteristics
- No prior prophylactic mastectomy
- No concurrent prophylactic mastectomy
Other
- More than 6 months since prior investigational drugs
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/05/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3864
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Newcastle Mater Hospital - Newcastle
Query!
Recruitment postcode(s) [1]
0
0
2310 - Newcastle
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Leuven
Query!
Country [2]
0
0
Chile
Query!
State/province [2]
0
0
Santiago
Query!
Country [3]
0
0
Denmark
Query!
State/province [3]
0
0
Horsholm
Query!
Country [4]
0
0
Finland
Query!
State/province [4]
0
0
Tampere
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Frankfurt
Query!
Country [6]
0
0
Hungary
Query!
State/province [6]
0
0
Szeged
Query!
Country [7]
0
0
Ireland
Query!
State/province [7]
0
0
Beaumont
Query!
Country [8]
0
0
Ireland
Query!
State/province [8]
0
0
Tallaght
Query!
Country [9]
0
0
Ireland
Query!
State/province [9]
0
0
Cork
Query!
Country [10]
0
0
Ireland
Query!
State/province [10]
0
0
Dublin
Query!
Country [11]
0
0
Ireland
Query!
State/province [11]
0
0
Galway
Query!
Country [12]
0
0
Ireland
Query!
State/province [12]
0
0
Limerick
Query!
Country [13]
0
0
Ireland
Query!
State/province [13]
0
0
Sligo
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Milan
Query!
Country [15]
0
0
Malta
Query!
State/province [15]
0
0
Floriana
Query!
Country [16]
0
0
Portugal
Query!
State/province [16]
0
0
Lisbon
Query!
Country [17]
0
0
Switzerland
Query!
State/province [17]
0
0
Bern
Query!
Country [18]
0
0
Switzerland
Query!
State/province [18]
0
0
Geneva
Query!
Country [19]
0
0
Switzerland
Query!
State/province [19]
0
0
Mendrisio
Query!
Country [20]
0
0
Switzerland
Query!
State/province [20]
0
0
St. Gallen
Query!
Country [21]
0
0
Switzerland
Query!
State/province [21]
0
0
Thun
Query!
Country [22]
0
0
Turkey
Query!
State/province [22]
0
0
Istanbul
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
England
Query!
Country [24]
0
0
United Kingdom
Query!
State/province [24]
0
0
Northern Ireland
Query!
Country [25]
0
0
United Kingdom
Query!
State/province [25]
0
0
Scotland
Query!
Country [26]
0
0
United Kingdom
Query!
State/province [26]
0
0
Wales
Query!
Country [27]
0
0
United Kingdom
Query!
State/province [27]
0
0
Aberdeen
Query!
Country [28]
0
0
United Kingdom
Query!
State/province [28]
0
0
Grantham
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Huddersfield
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
London
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Manchester
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Middlesex
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Newcastle
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Nottingham
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Oldham
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
Plymouth
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
Sheffield
Query!
Country [38]
0
0
United Kingdom
Query!
State/province [38]
0
0
Southampton
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
Stafford
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Truro
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Wishaw
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Yeovil
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Queen Mary University of London
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development of cancer. Anastrozole may be effective in preventing breast cancer.
PURPOSE: This randomized clinical trial is studying how well anastrozole works in preventing
breast cancer in postmenopausal women who are at increased risk for the disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00078832
Query!
Trial related presentations / publications
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2014 Dec;15(13):1460-1468. doi: 10.1016/S1470-2045(14)71035-6. Epub 2014 Nov 11. Erratum In: Lancet Oncol. 2014 Dec;15(13):e587. Lancet Oncol. 2014 Dec;15(13):e587.
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 2008 Oct;9(10):953-61. doi: 10.1016/S1470-2045(08)70207-9. Epub 2008 Sep 1.
Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum In: Lancet. 2014 Mar 22;383(9922):1040. Lancet. 2017 Mar 11;389(10073):1010.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jack Cuzick, PhD
Query!
Address
0
0
Queen Mary University of London
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00078832
Download to PDF